Lysozymes are ancient and important components of the innate immune system of animals that hydrolyze peptidoglycan, the major bacterial cell wall polymer. Bacteria engaging in commensal or pathogenic interactions with an animal host have evolved various strategies to evade this bactericidal enzyme, one recently proposed strategy being the production of lysozyme inhibitors. We here report the discovery of a novel family of bacterial lysozyme inhibitors with widespread homologs in gram-negative bacteria. First, a lysozyme inhibitor was isolated by affinity chromatography from a periplasmic extract of Salmonella Enteritidis, identified by mass spectrometry and correspondingly designated as PliC (periplasmic lysozyme inhibitor of c-type lysozyme). A pliC knock-out mutant no longer produced lysozyme inhibitory activity and showed increased lysozyme sensitivity in the presence of the outer membrane permeabilizing protein lactoferrin. PliC lacks similarity with the previously described Escherichia coli lysozyme inhibitor Ivy, but is related to a group of proteins with a common conserved COG3895 domain, some of them predicted to be lipoproteins. No function has yet been assigned to these proteins, although they are widely spread among the Proteobacteria. We demonstrate that at least two representatives of this group, MliC (membrane bound lysozyme inhibitor of c-type lysozyme) of E. coli and Pseudomonas aeruginosa, also possess lysozyme inhibitory activity and confer increased lysozyme tolerance upon expression in E. coli. Interestingly, mliC of Salmonella Typhi was picked up earlier in a screen for genes induced during residence in macrophages, and knockout of mliC was shown to reduce macrophage survival of S. Typhi. Based on these observations, we suggest that the COG3895 domain is a common feature of a novel and widespread family of bacterial lysozyme inhibitors in gram-negative bacteria that may function as colonization or virulence factors in bacteria interacting with an animal host.
Lysozyme is an ancient bactericidal enzyme that is part of the antibacterial defense system of vertebrate and invertebrate animals. Bacteria colonizing or infecting an animal host have developed various ways to overcome lysozyme action, a recently proposed mechanism being the production of lysozyme inhibitors. However, the only high affinity bacterial lysozyme inhibitor known thus far is produced only in few bacteria, and this raised questions about their wider relevance in bacteria–host interactions. We here report the discovery of a novel and distinct family of bacterial lysozyme inhibitors that is widely distributed among the Proteobacteria, including several major pathogens. The family comprises periplasmic as well as membrane-bound inhibitors, and both types contribute to lysozyme tolerance of bacterial cells, as we experimentally demonstrate for the periplasmic inhibitor from Salmonella Typhimurium and the membrane-bound inhibitors from Escherichia coli and Pseudomonas aeruginosa. Interestingly, a gene encoding one of the newly identified inhibitors has been previously found to promote macrophage survival of Salmonella Typhi. The widespread occurrence of lysozyme inhibitors in bacteria is likely to reflect their functional importance in a wide range of bacteria–host interactions. As such, they are also attractive novel targets for antibacterial drug development.
Citation: Callewaert L, Aertsen A, Deckers D, Vanoirbeek KGA, Vanderkelen L, Van Herreweghe JM, et al. (2008) A New Family of Lysozyme Inhibitors Contributing to Lysozyme Tolerance in Gram-Negative Bacteria. PLoS Pathog 4(3): e1000019. doi:10.1371/journal.ppat.1000019
Editor: Frederick M. Ausubel, Massachusetts General Hospital, United States of America
Received: December 6, 2007; Accepted: January 31, 2008; Published: March 7, 2008
Copyright: © 2008 Callewaert et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Authors L.C. and D.D. were supported by a doctoral fellowship from the Flemish Institute for the Promotion of Scientific Technological Research (IWT), author D.N. by a doctoral fellowship from the Directorate-General for Development Cooperation through the Belgian Technical Co-operation (BTC), author J.M.V.H. by a doctoral, and author A.A. by a postdoctoral fellowship from the Research Foundation-Flanders (FWO-Vlaanderen). This work was further financially supported by Research Grants from FWO-Vlaanderen (G.0308.05 and G.0363.08) and by the Research Fund K.U.Leuven (research project GOA/03/10). Sponsors or funders were not involved in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Lysozymes (EC 188.8.131.52) hydrolyse the β-(1,4) glycosidic bond between N-acetylmuramic acid and N-acetylglucosamine in peptidoglycan, the major cell wall polymer in the Bacteria. Peptidoglycan forms a network that surrounds the entire bacterial cell, and its hydrolysis by lysozyme renders bacteria sensitive to lysis driven by turgor pressure. Lysozymes are implicated in defensive and offensive bactericidal systems in a wide range of taxonomically diverse organisms including fungi, protozoa, plants, invertebrate and vertebrate animals and even bacteriophages, indicating their evolutionary success as bactericidal tools. Most gram-negative bacteria are not susceptible to the action of lysozyme alone because their outer membrane prevents access of the enzyme to the peptidoglycan layer. However, this barrier has been overcome in the innate immune systems of animals by the production of accessory antibacterial proteins which permeabilize the outer membrane, such as lactoferrin. In addition, some natural lysozymes as well as chemically or genetically modified hen egg white lysozyme (HEWL) have been reported to be active against gram-negative bacteria even in the absence of such permeabilizers –.
In view of the widespread occurrence and effectiveness of lysozymes as antibacterial agents, it is not surprising that bacteria have in turn evolved mechanisms to evade or subvert this threat. A bacterial lysozyme resistance mechanism that has been known for long is peptidoglycan modification. Examples are the de-N-acetylation of N-acetylglucosamine in Bacillus subtilis vegetative cells , and O-acetylation of the C-6 hydroxyl group of N-acetylglucosamine residues in Staphylococcus aureus and several other bacteria . In S. aureus, this modification is carried out by a peptidoglycan-specific O-acetyltransferase encoded by oatA, and is believed to contribute greatly to the persistence of pathogenic S. aureus strains on the skin and mucosal surfaces . A different bacterial strategy to evade the bactericidal action of lysozyme that has more recently emerged is the production of lysozyme inhibitors. In group A streptococci, a protein first identified as an inhibitor of the complement system and therefore designated as SIC (streptococcal inhibitor of complement), was later also shown to inhibit lysozyme . However, since SIC does not have a very high affinity for lysozyme (dissociation constant Kd = 85.4 µM), and also binds to and inhibits several other components of the innate immune system such as secretory leukocyte proteinase inhibitor and β-defensins at higher affinity ,, it can not be considered as a highly specific lysozyme inhibitor. A different lysozyme inhibitor, showing high affinity (Kd = 1 nM), was inadvertently identified during a systematic study of orphan gene products in Escherichia coli . The product of ykfE was shown to strongly bind to and inhibit c-type lysozymes, which include HEWL and human lysozymes, and was accordingly renamed Ivy (Inhibitor of vertebrate lysozyme). Using Ivy-deficient and Ivy-overexpressing E. coli strains, we demonstrated that Ivy contributes to lysozyme resistance of E. coli when the bacteria are simultaneously challenged with lactoferrin or with high hydrostatic pressure to permeabilize their outer membrane , and these findings fed speculations about a possible role for lysozyme inhibitors in bacterial interactions with vertebrate hosts. Pleading against such a role in a wide range of bacteria is the limited distribution of Ivy homologs (only in a few proteobacterial species) and in particular their apparent absence in the majority of gram-negative pathogens.
However, until now no dedicated function-based screenings for lysozyme inhibitors in bacteria have been reported, and thus the existence of bacterial lysozyme inhibitors different from Ivy can not be excluded. This possibility is supported by our recent observation of lysozyme inhibitory activity in crude cell extracts of Salmonella Typhimurium and S. Enteritidis which do not contain an ivy homolog in their genome ( and unpublished observation). In the current paper, we report the identification of this component as a novel type of periplasmic proteinaceous lysozyme inhibitor unrelated to Ivy and we demonstrate that this inhibitor contributes to lysozyme resistance in S. Enteritidis. Furthermore, two other members of the large but cryptic family of proteins with which this novel inhibitor shares a common structural motif are demonstrated to inhibit lysozyme, supporting the functional annotation of this protein family as bacterial lysozyme inhibitors.
Isolation and identification of a HEWL-inhibitor from S. Enteritidis
In previous work we tested the sensitivity of cell walls of different gram-negative bacteria against several lysozymes . To remove the outer membranes from these cells and make their cell walls accessible to lysozyme, we applied an extraction with chloroform-saturated buffer. A side observation in this work was that this procedure also allowed efficient extraction of the periplasmic lysozyme inhibitor Ivy from E. coli cells since extracts from the wildtype strain showed inhibitory activity against HEWL, while those from the Ivy− strain did not. Interestingly, extracts from S. Typhimurium also showed HEWL inhibition, although S. Typhimurium does not contain an Ivy homolog, nor do any of the other Salmonella serotypes from which a genome sequence is available. This observation was extended to extracts of S. Enteritidis (data not shown). Since we previously purified Ivy by a single HEWL affinity chromatography step to more than 95% purity starting from a periplasmic extract of E. coli overexpressing Ivy from a plasmid , we used the same approach and the same matrix (HEWL coupled to N-hydroxysuccinimide-activated Sepharose 4 Fast Flow resin) to isolate the putative lysozyme inhibitor from wildtype S. Enteritidis. When the periplasmic extract obtained from S. Enteritidis (inhibitory activity of 11.6 IU/ml) was passed over the affinity column, the flow-through fraction did no longer show HEWL inhibitory activity. The elution of the bound proteins, with their corresponding inhibitory activity, is shown in Figure 1. Two peaks of 27 and 20 milli absorption units were detected at elution volumes of respectively 19 ml and 27 ml, the latter coinciding with a single peak of HEWL inhibitory activity (67 IU/ml). SDS-PAGE analysis of this active fraction showed only a single band after Coomassie or silver staining (Figure 1). Material recovered from a Coomassie band was subjected to trypsin digestion and tandem mass spectrometry analysis allowing to identify with high confidence peptides (MASGANYEAIDK, MASGANYEAIDKNYTYK, TAELVEGDDK and TAELVEGDDKPVLSNCSLAN) corresponding to fragments of the predicted product of the SEN1802 open reading frame in the genome sequence of S. Enteritidis PT4 (Wellcome Trust Sanger Institute, Cambridge UK; http://www.sanger.ac.uk/). A SEN1802 homolog is present in S. Typhimurium LT2 and all other sequenced Salmonella genomes (National Centre for Biotechnology Information; http://www.ncbi.nlm.nih.gov/). The function of this gene product is unknown but it carries a predicted N-terminal signal peptide of 24 amino acids for Sec dependent transport to the periplasm. This prediction is in good agreement with our isolation of the protein from the periplasmic cell fraction and with its supposed activity as a lysozyme inhibitor. SEN1802 has two cysteines in its amino acid sequence for possible disulfide bridge formation, a calculated pI of 4.76 and a predicted molecular weight of 9981 Da (for 90 amino acid residues) after cleavage of the signal peptide. This is less than our molecular weight estimation from gel migration (14.4 kDa), but such a deviation is not uncommon for acidic proteins and has been ascribed to poor binding of SDS . Because of its HEWL inhibitory activity, we named the protein as PliC (periplasmic lysozyme inhibitor of c-type lysozyme).
Protein concentration in eluate was monitored by absorption at 280 nm [A280] and expressed in milli absorption units [mAU] (—), inhibitory activity of fractions against HEWL was monitored by inhibitor assay (-◊-). Elution was done with a gradient of 0–2.0 M KCl in 0.1 M Tris, pH 12.0 (·−·−·). Photograph in inset shows SDS-PAGE gel with molecular weight markers (lane 1, and indices in kDa at the left) and a concentrated fraction containing 0.163 mg/ml protein (without BSA addition) and an inhibitory activity of 323 IU/ml, corresponding to a specific activity of 1982 U/mg (lane 2).
Overexpression and knock-out of pliC in S. Enteritidis
To investigate the function of PliC in S. Enteritidis, a PliC knock-out (S. Enteritidis pliC) and PliC overexpression strain (S. Enteritidis pliC (pAA510)) were constructed. The level of PliC production by these strains in comparison to the wildtype strain was evaluated by analyzing the lysozyme inhibitory activity of crude periplasmic protein extracts (Figure 2). Knock-out of PliC resulted in a strong reduction of inhibitory activity in extracts of S. Enteritidis pliC (4.3 IU/ml) compared to wildtype extracts (29.0 IU/ml). Since the open reading frame downstream of pliC has an opposite orientation, this loss of inhibitory activity cannot be due to a polar effect of the knock-out. Introduction of the pAA510 plasmid in S. Enteritidis pliC rescued lysozyme inhibitory activity (176.5 IU/ml when grown in the presence of 0.2% arabinose to induce the cloned pliC gene. These results confirm that the lysozyme inhibitory activity in the periplasmic extracts can be ascribed to the PliC protein. It should be remarked that the inhibitory activity of the wildtype extract in this experiment was higher than in the extract used for chromatographical purification (29.0 IU/ml versus 11.6 IU/ml). This is due to variability of yield between different osmotic shock treatments (data not shown). However, the yields of samples that were simultaneously processed in a single osmotic shock treatment were reproducible for a particular strain.
Lysis (expressed as OD600 against time) of M. lysodeikticus cell suspension by 6.6 U/ml HEWL in the absence (-▪-) and presence of periplasmic protein extracts of S. Enteritidis pliC (1∶2 diluted; -▴-), S. Enteritidis (1∶10 diluted; —) and S. Enteritidis pliC (pAA510) (1∶40 diluted; -o-). Lysozyme inhibitory activity (IU/ml) of undiluted extracts is shown in the table in inset. The control sample (—) consisted of phosphate buffer instead of lysozyme solution added to M. lysodeikticus.
PliC protects S. Enteritidis against HEWL in the presence of lactoferrin
Suspensions of late exponential phase wildtype, pliC knock-out and pliC overexpression cells induced with arabinose were treated with 3.0 mg/ml lactoferrin, 100 µg/ml lysozyme, or a combination of both, and survivors were enumerated after 24 h (Figure 3). Most cells survived these treatments very well (inactivation levels not exceeding twofold), except for S. Enteritidis pliC cells in the presence of the lactoferrin - lysozyme mixture, which showed almost 15-fold inactivation. Lactoferrin is known to sensitize gram-negative bacteria to lysozyme and other antibacterial peptides by assisting their penetration through the outer membrane. Although the sensitizing action did not suffice to kill the wildtype S. Enteritidis under the conditions of our experiment, the fact that the pliC knock-out was sensitized demonstrates that natural levels of PliC were sufficient to protect S. Enteritidis cells against lysozyme.
Inactivation (No/N) of S. Enteritidis pliC, S. Enteritidis and S. Enteritidis pliC (pAA510) after 24 h of incubation with 10 mM Tris-HCl pH 7.0 (□), 100 µg/ml lysozyme (▪), 3.0 mg/ml lactoferrin (▪) and lysozyme and lactoferrin together (▪). Mean values ± standard deviations (error bars) are shown (n = 4). Lysozyme treatments resulting in significant differences (p<0.01) compared to the same treatments without lysozyme are marked with an asterisk.
Distribution of PliC relatives
An iterative search for sequences similar to the mature PliC protein using Psi-Blast  revealed besides the homologs in other Salmonella serotypes, similarity to proteins containing the conserved domain COG3895 (Clusters of Orthologous Groups,  http://www.ncbi.nlm.nih.gov/COG/). Proteins harboring this domain are widespread among members of the Proteobacteria, except the ε-Proteobacteria. Representatives are found in at least 52 different genera of the 155 completely sequenced genomes of all Proteobacteria available as to date (December 2007) and additionally occur in the Acidobacteria, Cyanobacteria and Bacteroides groups. The vast majority of COG3895 proteins are small proteins not containing other conserved protein domains and are predicted to be either periplasmic proteins (like PliC) or lipoproteins (, using the lipoprotein prediction tool available at http://www.mrc-lmb.cam.ac.uk/genomes/dolop/), but their function remains unknown. Also E. coli and Pseudomonas aeruginosa, which already have an active Ivy type lysozyme inhibitor ,, encode a COG3895 protein, respectively YdhA and PA0867. These two proteins are predicted to be anchored to the periplasmic side of the outer membrane ,. Because of their homology with PliC of Salmonella and their cellular localization in the bacterial cell, these proteins were renamed as MliC (membrane-bound lysozyme inhibitor of c-type lysozyme). This designation already anticipates on the functionality of these proteins as lysozyme inhibitors which will be demonstrated below. Although both bacteria, like Salmonella, belong to the γ-Proteobacteria, the two predicted MliC proteins share only 32% (over 53 amino acids) and 27% (over 65 amino acids) identity with PliC, and 38% identity (over 70 amino acids) with each other (Figure 4). Because of this relatively large distance and because a 3-D structure is available for MliC of E. coli (YdhA, ), MliC from E. coli and P. aeruginosa were chosen as representatives to further investigate the lysozyme inhibitory activity of the lipoprotein subgroup within the COG3895 group of proteins.
Amino acid sequence alignment (http://www.ebi.ac.uk/clustalw/, ) of MliC from P. aeruginosa ( = PA0867 from P. aeruginosa PA01), MliC from E. coli ( = YdhA from E. coli MG1655) (both proteins containing the COG3895 domain) and PliC from S. Enteritidis ( = SEN1802 from S. Enteritidis). Residues that are identical in all sequences in the alignment are marked with “*” in the bottom row, conserved and semi-conserved substitutions with “:” and “.” respectively. The lipobox of the lipoproteins is underlined, while cysteine residues of the mature protein are highlighted in grey.
In vitro HEWL-inhibitory activity of MliC proteins
mliC from P. aeruginosa and E. coli were cloned under control of an arabinose inducible promoter (pAA520 and pAA530 respectively) in an E. coli ivy mliC background, to avoid interference from endogenous E. coli inhibitors. Lysozyme inhibitory activity was measured in the periplasmic extracts and membrane fractions of the overexpression strains after induction and compared to that of the control strain E. coli ivy mliC without overexpression plasmid. No significant differences in lysozyme inhibitory activity were found in the periplasmic protein extracts (data not shown). On the other hand, while only 6.3 IU/ml inhibitory activity was detected in the membrane fraction of E. coli ivy mliC, much higher levels of inhibitory activity were measured in the extracts upon induction of MliC expression from P. aeruginosa (67.6 IU/ml) or MliC from E. coli (40.7 IU/ml) (Figure 5). Therefore, we can conclude that both MliC of P. aeruginosa and MliC of E. coli are HEWL-inhibitors.
Lysis (expressed as OD600 against time) of M. lysodeikticus cell suspension by 6.6 U/ml HEWL in the absence (-▪-) and presence of membrane protein extracts of E. coli ivy mliC (1∶2 diluted; -▴-), E. coli ivy (1∶2 diluted; —), E. coli ivy mliC (pAA520) expressing MliC from P. aeruginosa (1∶10 diluted; -□-) and E. coli ivy mliC (pAA530) expressing MliC from E. coli (1∶5 diluted; -o-). Lysozyme inhibitory activity (IU/ml) of undiluted extracts is shown in the table in inset. The control sample (—) consisted of phosphate buffer instead of lysozyme solution added to M. lysodeikticus. The protein concentration of the undiluted membrane protein extracts from the different strains was the same (0.310 ± 0.045 mg/ml).
It can also be seen in Figure 5, that knock-out of mliC in E. coli had almost no influence on the level of inhibitory activity of the membrane extracts (6.7 versus 6.3 IU/ml, for an ivy and an ivy mliC strain respectively). This is in line with earlier reports that mliC (previously ydhA) transcripts of E. coli are not detected under normal laboratory growth conditions .
Expression of the novel lysozyme inhibitors suppresses growth inhibition of E. coli by HEWL
To investigate the actual contribution of the inhibitors to bacterial HEWL resilience, E. coli ivy mliC was rendered sensitive to HEWL by introducing a tolA mutation that increases its outer membrane permeability. The resulting triple mutant was subsequently transformed with different plasmids that enable arabinose induced expression of either Ivy from E. coli (pAA410), PliC from S. Enteritidis (pAA510), MliC from P. aeruginosa (pAA520), and MliC from E. coli (pAA530). Next, we compared the growth inhibition by HEWL of these strains in the absence and in the presence of arabinose in the medium. At a HEWL concentration of 25 µg/ml, significant differences in optical density (OD600) and in plate counts (CFU/ml) of the cultures were observed upon induction of each inhibitor (Figure 6). Overexpression of Ivy, PliC of S. Enteritidis, MliC of P. aeruginosa or MliC from E. coli increased bacterial growth after 8 hours respectively 9, 7, 7 and 5-fold. A control construct (pAA100) containing the gene for green fluorescent protein (gfp) in the same vector and E. coli background, showed no significant differences in optical density or plate counts upon induction (data not shown). These results demonstrate that besides Ivy, also at least three members of the newly identified family of lysozyme inhibitors can effectively protect bacterial cells against lysozyme when expressed at appropriate levels.
Growth curves (OD600) of E. coli tolA ivy mliC harboring (A) pAA410 carrying Ivy from E. coli, (B) pAA510 carrying PliC from S. Enteritidis, (C) pAA520 carrying MliC from P. aeruginosa, and (D) pAA530 carrying MliC from E. coli, in the presence of 25 µg/ml HEWL and with (-▪-) or without (-□-) 0.02% arabinose. Bars represent viable cell numbers after 8 hours determined by plate count (log CFU/ml). Mean values ± standard deviations (error bars) are shown (n = 3).
In this work, we have identified a novel class of lysozyme inhibitors different from Ivy, the lysozyme inhibitor discovered earlier in E. coli . These novel inhibitors belong to a large family of proteobacterial predicted periplasmic proteins or lipoproteins which share a common COG3895 structural motif with unknown function. We demonstrated lysozyme inhibitory activity for one periplasmic (PliC from S. Enteritidis), as well as for two lipoprotein members of this family (MliC from P. aeruginosa and from E. coli). Although no function had hitherto been assigned to any of the COG3895 proteins the 3-D solution structure of MliC from E. coli has been recently resolved, featuring an 8-stranded β-barrel, stabilized by a disulfide bond . At the 3-D level, there is no resemblance with Ivy, which adopts a central β-sheet made of 5 antiparallel β-strands flanked on the convex side by two short helices and on the concave side by an amphipathic helix . The Cys residues engaging in the disulfide bond in MliC from E. coli are conserved in both PliC from S. Enteritidis and MliC from P. aeruginosa, and in the majority of COG3895 proteins, suggesting that they may be important for preserving conformational stability.
The existence and possible function of lysozyme inhibitors in bacteria has not received much attention thus far. To our knowledge, a systematic screen for bacterial lysozyme inhibitors has not yet been conducted. This is surprising, given the important role of lysozymes in antibacterial defense in all major eukaryotic lineages, and the extensively documented existence of inhibitors of various other glycosyl hydrolases. Particularly plants produce a wide range of such inhibitors, for example against polygalacturonases, xylanases, α-amylases and β-glucanases, to thwart microbial attack. Therefore, the discovery in this work of a novel class of bacterial lysozyme inhibitors and the wide distribution of homologs of these inhibitors in the Proteobacteria may be indicative for their functional importance, for example in bacteria-host interactions. The location of the bacterial lysozyme inhibitors either in the periplasm (Ivy and PliC from S. Enteritidis), or anchored to the luminal face of the outer membrane (MliC from E. coli and P. aeruginosa) is also consistent with a role in protecting peptidoglycan from hydrolysis by exogenous lysozymes. In at least one instance more direct evidence for a role in host interaction exists. In Salmonella Typhi, expression of the mliC homolog was induced in cells residing within macrophages and knockout of mliC reduced macrophage survival . Macrophages are known to produce a battery of antibacterial peptides including lysozyme and membrane permeabilizers, and hence the production of one or more lysozyme inhibitors by intracellular pathogens like S. Typhi makes sense from this point of view. The observed increased lysozyme sensitivity of an S. Enteritidis pliC knockout in the presence of 3.0 mg/ml of the outer membrane permeabilizing protein lactoferrin (Figure 3) provides a relevant indication in this context. Lactoferrin concentrations in this range occur in secretions like tears, airway mucus or colostrum ,,. Moreover, Ivy and all three new HEWL-inhibitors identified in this study suppressed growth inhibition by HEWL when overexpressed in an E. coli MG1655 tolA ivy mliC strain (Figure 6).
The genomic context of the newly identified lysozyme inhibitor genes also provides some interesting clues about their possible function. Immediately upstream of pliC of S. Typhimurium are the genes pagC, pagD and msgA, which play a role in macrophage survival of S. Typhimurium. Furthermore, transcriptome analysis has revealed that expression of pliC is controlled by SlyA, the same transcriptional activator that controls expression of pagC and pagD and that is necessary for virulence . Based on its low GC content, the region encompassing pagC and a number of its immediate upstream genes was suggested to be acquired by lateral gene transfer, as is often the case for virulence genes . The pliC gene, which is immediately downstream of pagC, also has a markedly lower GC content (42.0%) than the average of the LT2 chromosome (52.2%), and thus probably is an integral part of this acquired genome fragment. Interestingly, the mliC gene is located downstream of slyA in all sequenced Salmonella strains. Furthermore, both in E. coli and in Salmonella, mliC or its homolog are adjacent to ydhH, an open reading frame recently renamed to anmK because it encodes an anhydro N-acetyl muramic acid kinase involved in recycling of murein . This allows speculation on a possible role of MliC in murein recycling, for example by controlling excessive hydrolysis of the murein backbone by lytic transglycosylases. However, at present we do not know whether the latter enzymes are inhibited by MliC or any of the other COG3895 proteins.
C-type lysozymes (e.g. HEWL or human lysozyme) are the major lysozymes produced by most vertebrates. In addition, all vertebrates have genes encoding g-type lysozyme. While the importance of the latter is not clear in man, it is the dominant type in some birds and it also occurs in fish species. A third type of lysozyme, called i-type, is characteristic for invertebrate animals such as arthropods, molluscs, nematodes etc. . Neither PliC from S. Enteritidis, nor MliC from E. coli or P. aeruginosa have inhibitory activity against g-type lysozyme from goose egg white (data not shown). Ivy, in contrast, is active against goose egg white lysozyme  but not against g-type lysozyme from the urochordate Oikopleura dioica and i-type lysozyme from the scallop Chlamys islandica . Given the existence and widespread occurrence of two types of c-type-specific lysozyme inhibitors in Proteobacteria, we anticipate that additional inhibitor classes specific against other types of lysozymes are also likely to be produced in bacteria. Screening of crude periplasmic extracts of a diverse range of bacteria for inhibitory activity against these g- and i-type lysozymes seems to corroborate this assumption (unpublished results), but definitive confirmation will have to await isolation and identification of the putative inhibitors.
The possible effect of bacterial lysozyme inhibitors in bacterial pathogenesis may even extend beyond neutralizing the direct antibacterial effect of lysozyme. Peptidoglycan has recently emerged as a powerful effector of the innate immune system through interaction with specific host receptors. The actual elicitor molecules are specific muropeptide fragments derived from peptidoglycan by bacterial and/or host lytic enzymes ,. This system of pattern recognition is believed to allow the host to distinguish pathogenic from non-pathogenic bacteria and to maintain its immune functions at an appropriate level. Malfunctioning of this system has been linked to chronic immune-related diseases such as inflammatory bowel disease and Crohn's disease. By interfering with the fragmentation of peptidoglycan by host lysozymes, bacterial lysozyme inhibitors can be anticipated to influence this system, and thus to play a potential role in these immune related pathologies. Provided that their role in bacterial pathogenesis can be further substantiated, bacterial lysozyme inhibitors may constitute an attractive new target for the development of anti-inflammatory and/or immunomodulating drugs.
In conclusion, we have identified a novel family of bacterial lysozyme inhibitors that contribute to bacterial lysozyme resistance and that have widespread homologs in gram-negative bacteria. Further study of these inhibitors will not only improve our understanding of bacteria-host interactions, lysozyme inhibitors may also turn out to be interesting novel targets for drug development.
Materials and Methods
Bacterial strains, plasmids, and culture conditions
Bacterial strains and plasmids used in this study are listed in Table 1. Construction of mutants and plasmids is discussed in Text S1. Where appropriate, plasmids were transformed to bacteria by electroporation.
All strains were originally cultured on Luria Bertani (LB; 10 g/l trypton, 5 g/l yeast extract, 5 g/l NaCl) agar plates and incubated at 37°C for 21 h. Overnight broth cultures were obtained by inoculating a single colony into LB broth containing appropriate antibiotics and incubating at 37°C for 21 h with aeration. Antibiotics (Sigma-Aldrich, Bornem, Belgium) were added when necessary to obtain the following final concentrations: 100 µg/ml ampicillin, 50 µg/ml kanamycin or 20 µg/ml chloramphenicol.
Purification of HEWL-inhibiting proteins
For the purification of PliC, 500 ml cultures of S. Enteritidis ATCC 13076 were grown on a rotary shaker to stationary phase (21 h, shaking at 200 rpm) in LB at 37°C. Periplasmic cell extracts were then prepared by a gentle cold osmotic shock procedure as described earlier , and stored at −20°C until further analysis. Lysozyme binding inhibitors were isolated from this periplasmic cell fraction on an ÄKTA-FPLC platform (Amersham Pharmacia Biotech, Upsalla, Sweden) by affinity chromatography using immobilized HEWL as a ligand as described earlier for the Ivy protein , except that 100 ml of crude extract was loaded rather than 25 ml, and fractions of 5.0 ml rather than 2.0 ml were collected. The fractions were collected in tubes containing 300 µl of 1.0 M Tris-HCl pH 8.0 to neutralize the high pH of the elution buffer (pH 12.0), and bovine serum albumin (BSA, Sigma-Aldrich) was added to a final concentration of 0.5 mg/ml to stabilize the purified protein unless the samples were used for SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Fractions were then desalted by dialysis against 10 mM potassium phosphate buffer pH 7.0 (12 kDa cut off, Sigma-Aldrich) and stored at −20°C until further use.
After purification, protein purity was checked with SDS-PAGE, conducted according to  with a 15% separating gel and a 4% stacking gel. Samples were prepared by boiling for 3 min in the presence of 1% ß-mercaptoethanol and 1% SDS. Gels were stained with Coomassie blue R 250 (Sigma-Aldrich), and, if higher sensitivity was desired, destained and subsequently silver-stained following the procedure of .
For the isolation of MliC of P. aeruginosa or E. coli, cultures of E. coli ivy mliC harboring plasmid pAA520 or pAA530 respectively, were grown overnight at 37°C in LB with ampicillin (100 µg/ml, Sigma-Aldrich), diluted 1/100 in fresh LB without antibiotics, induced with 0.2% (w/v) L−(+)-arabinose after 4 hours of growth, and further incubated at 37°C until stationary phase. Portions of 200 ml were subsequently harvested, resuspended in 10 ml 10 mM Tris-HCl pH 8 and lysed by three cycles of freezing and thawing followed by sonication (3×3 min, amplitude 40%, pulses 5 s on/5 s off). These suspensions were centrifuged for 1 hour at 100.000×g (4°C). The resulting pellet was resuspended in 10 ml 10 mM Tris-HCl buffer (pH 6.8) supplemented with 1.0 M NaCl, and sedimented again as described above. The membrane-bound proteins were then extracted using 2% Triton X-100 in a 10 mM Tris-HCl buffer (pH 6.8) supplemented with 10 mM MgCl2 and 150 mM NaCl and separated from insoluble material by centrifugation (1 hour at 100.000×g, 4°C).
Protein identification by mass spectrometry
Active fractions containing the purified inhibitor protein were lyophilized, redissolved and subjected to SDS-PAGE and Coomassie staining. A gel fragment from the band corresponding to the inhibitor was trypsin-digested according to the method of , and the digests were then analyzed by electrospray tandem mass spectrometry on a LCQ Classic (ThermoFinnigan, San Jose, California) ion trap mass spectrometer equipped with a nano-liquid chromatography column switching system and a nanoelectrospray device. Tandem mass spectrometry data were searched using MASCOT (Matrix Sciences, London, U.K.) and SEQUEST (ThermoFinnigan) against the GenBank non-redundant protein database.
Determination of HEWL inhibitory activity
Freeze-dried M. lysodeikticus ATCC4698 cells (Sigma-Aldrich) were resuspended at 0.5 mg/ml either in appropriate dilutions of the bacterial crude extracts, purified column fractions or in potassium phosphate buffer (10 mM, pH 7.0) with 0.5 mg/ml Bovine Serum Albumine (BSA) for the controls. Thirty µl of 66 U/ml HEWL (Hen Egg White Lysozyme; Fluka, 66000 U/mg protein) in potassium phosphate buffer (10 mM, pH 7.0) was then added to 270 µl of these suspensions and cell lysis was followed during 2 h at 25°C as the decrease in optical density (OD600) using a Bioscreen C Microbiology Reader (Labsystems Oy, Helsinki, Finland). In the absence of inhibitor, this procedure resulted in a linear OD600 decrease of 0.27 ± 0.04 over 2 h. The percentage inhibition (I) for each column fraction was calculated as:with L0 − L, R0 − R and B0 − B representing the OD600 decrease over a period of 2 h of the M. lysodeikticus suspensions respectively in the presence of lysozyme but with buffer instead of a bacterial extract/column fraction, in the presence of the bacterial extract/column fraction and lysozyme, and in the presence of the bacterial extract/column fraction but with buffer instead of lysozyme. Inhibitory activity was expressed in inhibitory units, with one unit being the amount of inhibitor that is needed to decrease the lysozyme activity by 50% under the above assay conditions.
Sensitivity of S. Enteritidis to lysozyme in the presence of lactoferrin
S. Enteritidis, S. Enteritidis pliC and S. Enteritidis pliC (pAA510) cultures were grown overnight in LB with ampicillin and/or chloramphenicol when appropriate, diluted 1/100 in fresh LB without antibiotics, induced with 0.2% (w/v) L−(+)-arabinose (Fluka, Buchs, Switzerland), and incubated further. Arabinose served only to induce pliC expression from plasmid pAA510, but was also added to cultures of strains not carrying this plasmid to ensure identical culture conditions for all strains in the experiment. At an optical density (OD600) of 0.6 (5.108 ± 1.108 CFU/ml), cells were harvested by centrifugation (3800×g, 5 min) and subsequently resuspended in the same volume of Tris-HCl buffer (10 mM; pH 7.0) without and with lactoferrin (gift from Morinaga Milk Industries, Kanagawa, Japan; 3.0 mg/ml final concentration) and/or HEWL (Fluka, 66000 U/mg protein; 100 µg/ml final concentration). Samples were serially diluted in sterile Tris-HCl buffer (10 mM; pH 7.0) at the beginning and after 24 hours of treatment, and plated on LB agar plates to determine the degree of inactivation. Inactivation was expressed as a viability reduction factor, No/N, with No and N respectively the colony counts at the beginning and after 24 hours of treatment.
Lysozyme growth inhibition in vivo
Precultures of E. coli MG1655 tolA ivy mliC harboring plasmid pAA410, pAA510, pAA520, or pAA530 were grown overnight in LB broth containing ampicillin, kanamycin and chloramphenicol. Subsequently, cultures were diluted (1/100) in duplicate in fresh LB containing ampicillin, and after three hours of growth (exponential phase), either H2O or 0.02% L−(+)-arabinose was added, resulting in control and induced precultures respectively. These cultures were further grown to stationary phase to allow inhibitor expression. Subsequently, test tubes containing 4 ml LB with ampicillin, and either water or 0.02% L−(+)-arabinose and 25 µg/ml HEWL were inoculated (1/100) with the control and induced E. coli precultures respectively. These cultures were grown at 37°C during 10 hours. Each hour the OD600 was determined using a Multiscan RC (Thermo Scientific, Zellik, Belgium). After 8 hours the viable cell number was enumerated by plating on LB agar.
List of geneID numbers
From E. coli MG1655: ivy (before ykfE): 946530 (Gene Entrez), mliC (before ydhA): 946811 (Gene Entrez), tolA: 946625 (Gene Entrez); From P. aeruginosa: mliC (before PA0867): 882238 (Gene Entrez); From Salmonella Enteritidis: pliC: SEN1802 (http://www.sanger.ac.uk/).
The construction of the S. Enteritidis pliC knock-out mutant, the E. coli ivy mliC mutant, the E. coli tolA ivy mliC mutant and the construction of the plasmids pAA510, pAA520 and pAA530 is described.
(0.04 MB DOC)
Conceived and designed the experiments: LC BM CWM. Performed the experiments: LC AA DD KGAV LV JMH JR. Analyzed the data: LC AA BM CWM. Contributed reagents/materials/analysis tools: LC DD DN JR. Wrote the paper: LC AA CWM.
- 1. Grinde B (1989) A lysozyme isolated from rainbow trout acts on mastitis pathogens. FEMS Microbiol Lett 60(2): 179–182.
- 2. Nilsen IW, Øverbø K, Sandsdalen E, Sandaker E, Slettent K, et al. (1999) Protein purification and gene isolation of chlamysin, a cold-active lysozyme-like enzyme with antibacterial activity. FEBS Letters 464: 153–158.
- 3. Pellegrini A, Thomas U, Bramaz N, Klauser S, Hunziker P, et al. (1997) Identification and isolation of a bactericidal domain in chicken egg white lysozyme. J Appl Microbiol 82: 372–387.
- 4. Düring K, Porsch P, Mahn A, Brinkmann O, Gieffers W (1999) The non-enzymatic microbicidal activity of lysozymes. FEBS Letters 449: 93–100.
- 5. Zipperle GF, Ezzell JW, Doyle RJ (1984) Glucosamine substitution and muramidase susceptibility in Bacillus anthracis. Can J Microbiol 30: 553–559.
- 6. Clarke A, Dupont C (1992) O-acetylated peptidoglycan: its occurence, pathobiological significance, and biosynthesis. Can J Microbiol 38: 85–91.
- 7. Bera A, Herbert S, Jakob A, Vollmer W, Götz F (2005) Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol Microbiol 55: 778–787.
- 8. Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ (2002) Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. Infect Immun 70(9): 4908–4916.
- 9. Fernie-King BA, Seilly DJ, Binks MJ, Sriprakash KS, Lachmann PJ (2007) Streptococcal DRS (distantly related to SIC) and SIC inhibit antimicrobial peptides, components of mucosal innate immunity: a comparison of their activities. Microbes Infect 9: 300–307.
- 10. Monchois V, Abergel C, Sturgis J, Jeudy S, Claverie JM (2001) Escherichia coli ykfE ORFan gene encodes a potent inhibitor of c-type lysozyme. J Biol Chem 276: 18437–18441.
- 11. Deckers D, Masschalck B, Aertsen A, Callewaert L, Van Tiggelen CGM, et al. (2004) Periplasmic lysozyme inhibitor contributes to lysozyme resistance in Escherichia coli. Cell Mol Life Sci 61: 1229–1237.
- 12. Nakimbugwe D, Masschalck B, Deckers D, Callewaert L, Aertsen A, et al. (2006) Cell wall substrate specificity of six different lysozymes and lysozyme inhibitory activity of bacterial extracts. FEMS Microbiol Lett 259: 41–46.
- 13. Callewaert L, Masschalck B, Deckers D, Nakimbugwe D, Atanassova M, et al. (2005) Purification of Ivy, a lysozyme inhibitor from Escherichia coli, and characterisation of its specificity for various lysozymes. Enzyme Microb Technol 37(2): 205–211.
- 14. Kaufmann E, Geisler N, Weber K (1984) SDS-PAGE strongly overestimates the molecular masses of the neurofilament proteins. FEBS Lett 170(1): 81–84.
- 15. Schäffer AA, Aravind L, Madden TL, Shavirin S, Spouge JL, et al. (2001) Improving the accuracy of PSI-BLAST protein database searches with composition-based statistics and other refinements. Nucleic Acids Res 29(14): 2994–3005.
- 16. Tatusov RL, Fedorova ND, Jackson JD, Jacobs AR, Kiryutin B, et al. (2003) The COG database: an updated version includes eukaryotes. BMC Bioinformatics 4: 41.
- 17. Babu MM, Priya ML, Selvan AT, Madera M, Gough J, et al. (2006) A database of bacterial lipoproteins (DOLOP) with functional assignments to predicted lipoproteins. J Bacteriol 188: 2761–2773.
- 18. Abergel C, Monchois V, Byrne D, Chenivesse S, Lembo F, et al. (2007) Structure and evolution of the Ivy protein family, unexpected lysozyme inhibitors in gram-negative bacteria. Proc Nat Ac Sci 104(15): 6394–6399.
- 19. Tokuda H, Matsuyama S-I (2004) Sorting of lipoproteins to the outer membrane in E. coli. Biochim Biophys Acta 1693: 5–13.
- 20. Narita S-I, Tokuda H (2007) Amino Acids at Positions 3 and 4 Determine the Membrane Specificity of Pseudomonas aeruginosa Lipoproteins. J Biol Chem 282(18): 13372–13378.
- 21. Revington M, Semesi A, Yee A, Arrowsmith CH, Shaw GS (2006) The solution structure of the protein ydhA from Escherichia coli. J Biomol NMR 35: 295–300.
- 22. Lam H-M, Winkler ME (1992) Characterization of the complex pdxH-tyrS operon of Escherichia coli K-12 and pleiotropic phenotypes caused by pdxH insertion mutations. J Bacteriol 174: 6033–6045.
- 23. Daigle F, Graham JE, Curtis R III (2001) Identification of Salmonella typhi genes expressed within macrophages by selective capture of transcribed sequences (SCOTS). Mol Microbiol 41(5): 1211–1222.
- 24. Marthur NB, Dwarkadas AM, Sharma VK, Saha K, Jain N (1990) Anti-infective factors in preterm human colostrum. Acta Paediatr Scand 79: 1039–1044.
- 25. Thompson AB, Bohling T, Payvandi F, Rennard SI (1990) Lower respiratory tract lactoferrin and lysozyme arise primarily in the airways and are elevated in association with chronic bronchitis. J Lab Clin Med 115: 148–158.
- 26. Ng V, Cho P, Mak S, Lee A (2000) Variability of tear protein levels in normal young adults: between –day variation. Graefe's Arch Clin Exp Ophtalmol 238: 892–899.
- 27. Navarre WW, Halsey TA, Walthers D, Frye J, McClelland M, et al. (2005) Co-regulation of Salmonella enterica genes required for virulence and resistance to antimicrobial peptides by SlyA and PhoP/PhoQ. Mol Microbiol 56(2): 492–508.
- 28. Gunn JS, Alpuche-Aranda CM, Loomis WP, Belden WJ, Miller SI (1995) Characterization of the Salmonella typhimurium pagC/pagD chromosomal region. J Bacteriol 177(17): 5040–5047.
- 29. Uehara T, Suefuji K, Valbuena N, Meehan B, Donegan M, et al. (2005) Recycling of the anhydro-N-acetylmuramic acid derived from cell wall murein involves a two-step conversion to N-acetylglucosamine-phosphate. J Bacteriol 187(11): 3643–3649.
- 30. Ito Y, Yoshikawa A, Hotani I, Fukuda S, Sugimura K, et al. (1999) Amino acid sequences of lysozymes newly purified from invertebrates implay wide distribution of a novel class in the lysozyme family. Eur J Biochem 259: 456–461.
- 31. Nilsen IW, Myrnes B, Edvardsen RB, Chourrout D (2003) Urochordates carry multiple genes for goose-type lysozyme and no genes for chicken- or invertebrate-type lysozymes. Cell Mol Life Sci 60: 2210–2218.
- 32. Boneca IG (2005) The role of peptidoglycan in pathogenesis. Curr Opin Microbiol 8: 46–53.
- 33. Traub S, von Aulock S, Hartung T, Hermann C (2006) MDP and other muropeptides - direct and synergistic effects on the immune system. J Endotoxin Res 12(2): 69–85.
- 34. Laemmli M (1970) Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature 227: 680–685.
- 35. Heukeshoven J, Dernick R (1988) Improved silver staining procedure for fast staining in PhastSystem Development Unit. I. Staining of sodium dodecyl sulfate gels. Electrophoresis 9: 28–32.
- 36. Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins from silver stained polyacrylamide gels. Anal Chem 68: 850–858.
- 37. Higgins D, Thompson J, Gibson T, Thompson JD, Higgins DG, et al. (1994) CLUSTAL W: improving the sensitivity of progressivemultiple sequence alignment through sequence weighting,position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673–4680.
- 38. Blattner FR, Plunkett G III, Bloch CA, Perna NT, Burland V, et al. (1997) The complete genome sequence of Escherichia coli K-12. Science 277(5331): 1453–1462.
- 39. Kang Y, Durfee T, Glasner JD, Qiu Y, Frisch D, et al. (2004) Systematic Mutagenesis of the Escherichia coli Genome. J Bacteriol 186(15): 4921–4930.
- 40. Nicas TI, Hancock REW (1980) Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol 143(2): 872–878.
- 41. Aertsen A, Tesfazgi Mebrhatu M, Michiels CW (2008) Activation of the Salmonella Typhimurium Mrr protein. Biochem Biophys Res Commun. In press.